News

The European Commission has granted orphan medicinal product designation to Cereno Scientific’s CS1 for the treatment of people with pulmonary arterial hypertension (PAH). This designation is given to medications for life-threatening or chronically debilitating diseases, affecting up to five per 10,000 individuals in the European Union (EU), or…

Liquidia is suing the U.S. Food and Drug Administration (FDA) to challenge a decision that delays the final approval of Yutrepia, its inhaled dry-powder formulation of treprostinil, arguing that the delay unfairly limits patient access to important treatment. Yutrepia was granted tentative approval in 2021 to improve the…

Winrevair (sotatercept-csrk), Merck’s injection therapy for adults with pulmonary arterial hypertension (PAH), has been approved in the European Union, as well as in Iceland, Liechtenstein, and Norway. The approval from the European Commission specifically covers Winrevair when used in combination with other PAH therapies to improve…

Airplane travel appears to be safe for people with pulmonary hypertension (PH) with both slight and marked limitations of physical activity, though some individuals may need oxygen support on board to help with breathing, according to a new study. While some patients in the study, dubbed PEGASUS (NCT03051763),…

The protein asporin was identified as a possible biomarker of disease severity and to be protective in pulmonary arterial hypertension (PAH), a study suggests that used lung and blood samples from people with the disease. The protein was increased in PAH patients and correlated with reduced disease severity. In…

The U.S. Food and Drug Administration (FDA) has extended its tentative approval of Yutrepia, an inhaled dry powder formulation of treprostinil, to pulmonary hypertension associated with interstitial lung disease (PH-ILD), a condition that causes the lungs to become scarred. Liquidia’s Yutrepia was granted tentative approval in 2021…

People with interstitial lung disease face higher healthcare resource utilization (HCRU) and increased medical costs if they are also diagnosed with pulmonary hypertension (PH-ILD), according to a U.S. study. Factors associated with increased burden and costs include a significantly higher need for inpatient care, longer hospitalizations,  as well as…

Tenax Therapeutics has raised about $100 million in private funding to help accelerate the clinical development of oral levosimendan (TNX-103), a potential therapy for pulmonary hypertension(PH) due to heart failure with preserved ejection fraction (PH-HFpEF). The funding will help complete the ongoing placebo-controlled Phase 3 LEVEL…

People with pulmonary hypertension (PH) see worse outcomes following surgery to correct a hip fracture, a study shows. Among hip fracture patients, PH was associated with higher rates of post-surgical mortality, major in-hospital complications, and hospital re-admissions within three months. Those with severe PH had the worst outcomes after…

For people with pulmonary arterial hypertension (PAH) both with and without a few co-occurring heart problems, combination therapy with macitentan and tadalafil is similarly effective, according to a new analysis by researchers in the U.S. and Europe. “Initial combination therapy with macitentan plus tadalafil is efficacious in patients with…

Children of cigarette-smoking parents are at greater risk of developing pulmonary arterial hypertension (PHA) within a year after birth, according to a new study by researchers in Iran. Specifically, almost half of babies exposed to parental cigarette smoke were diagnosed with PAH, while none of the children with nonsmoking…

How chronic thromboembolic pulmonary hypertension (CTEPH) is managed across regions globally varies widely despite treatment advances, a survey study found, highlighting the need for more research, better guidelines, and ongoing education for healthcare providers. The study, “Treatment and management of chronic thromboembolic pulmonary hypertension (CTEPH): A…